Regeneron Pharmaceuticals Inc. buy mnake
Summary
This prediction ended on 09.03.17 with a price of €366.35. The BUY prediction by mnake finished with a performance of 8.06%. mnake has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 5.324% | 5.324% | 19.781% | 118.463% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by mnake for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
intuitiv am unteren Limit
Regeneron bewegt sich aus meiner Sicht mal wieder am unteren Limit, so ist die Chance größer als das Risiko, zumal sich die Aussichten verbessert haben.
Stopped prediction by mnake for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
04.07.17
04.01.18
04.01.18
Regeneron Pharmaceuticals Inc.
11.03.16
01.08.16
01.08.16
Regeneron Pharmaceuticals Inc.
15.12.14
20.01.15
20.01.15